Cyclophosphamide for interstitial lung disease-associated acute respiratory failure: mortality, clinical response and radiological characteristics

Johanna P. van Gemert1,6*, Inge A. H. van den Berk2, Esther J. Nossent3, Leo M. A. Heunks4, Rene E. Jonkers5, Alexander P. Vlaar1 and Peter I. Bonta5

Abstract

Background: Treatment for interstitial lung disease (ILD) patients with acute respiratory failure (ARF) is challenging, and literature to guide such treatment is scarce. The reported in-hospital mortality rates of ILD patients with ARF are high (62–66%). Cyclophosphamide is considered a second-line treatment in steroid-refractory ILD-associated ARF. The first aim of this study was to evaluate the in-hospital mortality in patients with ILD-associated ARF treated with cyclophosphamide. The second aim was to compare computed tomographic (CT) patterns and physiological and ventilator parameters between survivors and non-survivors.

Methods: Retrospective analysis of patients with ILD-associated ARF treated with cyclophosphamide between February 2016 and October 2017. Patients were categorized into three subgroups: connective tissue disease (CTD)-associated ILD, other ILD or vasculitis. In-hospital mortality was evaluated in the whole cohort and in these subgroups. Clinical response was determined using physiological and ventilator parameters: Sequential Organ Failure Assessment Score (SOFA), PaO2/FiO2 (P/F) ratio and dynamic compliance (Cdyn) before and after cyclophosphamide treatment. The following CT features were quantified: ground-glass opacification (GGO) proportion, reticulation proportion, overall extent of parenchymal disease and fibrosis coarseness score.

Results: Fifteen patients were included. The overall in-hospital mortality rate was 40%. In-hospital mortality rates for CTD-associated ILD, other ILD and vasculitis were 20, 57, and 33%, respectively. The GGO proportion (71% vs 45%) was higher in non-survivors. There were no significant differences in the SOFA score, P/F ratio or Cdyn between survivors and non-survivors. However, in survivors the P/F ratio increased from 129 to 220 mmHg and Cdyn from 75 to 92 mL/cmH2O 3 days after cyclophosphamide treatment. In non-survivors the P/F ratio hardly changed (113–114 mmHg) and Cdyn even decreased (27–20 mL/cmH2O).

Conclusion: In this study, we found a mortality rate of 40% in patients treated with cyclophosphamide for ILD-associated ARF. Connective tissue disease-associated ILD and vasculitis were associated with a lower risk of death.
Background

Acute respiratory failure (ARF) is one of the most severe complications of interstitial lung disease (ILD). Patients with severe ARF require mechanical ventilation in the intensive care unit (ICU). The reported in-hospital mortality rates of ILD patients with ARF are high, and the outcomes of the different ILD subtypes are quite variable. For a mixed population of ILD patients with ARF, in-hospital mortality rates are as high as 66% [1]. The highest mortality rates in patients with ARF are reported for idiopathic pulmonary fibrosis (IPF) (73–100%), while mortality rates in connective tissue disease (CTD)-associated ILD (62%) and drug-induced ILDs (64%) are slightly lower [1–3]. Treatment of patients with ILD-associated ARF is particularly challenging. Intravenous corticosteroid therapy is the initial treatment of choice for ILD-associated ARF. According to British Thoracic Society (BTS) guidelines, initial treatment of choice for ILD-associated ARF is corticosteroids before receiving cyclophosphamide according to the BTS guidelines [4]. For vasculitis, the combination of corticosteroid therapy and intravenous cyclophosphamide or rituximab is considered the first-line treatment [5]. However, for patients with ILD-associated ARF there are no randomized controlled trials available. Overall, the optimal treatment strategy to manage the heterogeneous groups of ILD patients with ARF in the ICU is not well established.

Radiologic evaluation through computed tomography (CT) is essential for the characterization and classification of ILD. Limited data are available on how parenchymal changes on CT scans can predict prognosis in ILD patients with severe respiratory failure in need of invasive ventilation.

In this study, we focused on the clinical response and radiological characteristics of mechanically ventilated patients who received cyclophosphamide for ILD-associated ARF. As ILDs are a very heterogeneous group of diseases with several different causes, patients were categorized into 3 subgroups: connective tissue disease (CTD)-associated ILD, other ILD (non-IPF) or vasculitis.

The first aim of this study was to evaluate in-hospital mortality in the whole cohort and in the 3 different subgroups. The second aim was to compare computed tomographic (CT) patterns and physiological and ventilator parameters between survivors and non-survivors.

Material and methods

Patients

Data were collected from adult patients with ILD-associated ARF who were mechanically ventilated and treated with cyclophosphamide at the ICUs of two tertiary teaching hospitals in the Netherlands between February 2016 and October 2017. All surviving patients provided written informed consent to the study. Data collection was performed in accordance with the institutional guidelines. ILD diagnosis was defined based on the American Thoracic Society/European Respiratory Society classification of idiopathic interstitial pneumonias and the EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis [5, 6]. The diagnosis was confirmed by formal multidisciplinary team discussion. All patients were treated with intravenous corticosteroids before receiving cyclophosphamide according to the BTS guidelines [4]. Steroid-refractory disease was defined as lack of clinical improvement or progressive respiratory failure despite adequate ventilation after corticosteroid treatment [4]. Patients were categorized into three subtypes: CTD-associated ILD, other ILD or vasculitis. Patients with IPF were not included in the study. IPF patients with ARF are generally not intubated or treated with cyclophosphamide in the participating hospitals. Demographic, diagnostic and clinical data were taken from the medical records. The primary end-point was in-hospital mortality. Secondary endpoints were computed tomographic (CT) patterns and clinical response. Clinical response was determined using the following physiological and ventilatory parameters: Sequential Organ Failure Assessment Score (SOFA), PaO2/FiO2 ratio (P/F ratio) and dynamic compliance (Cdyn) before and 3 days after cyclophosphamide treatment.

Quantification of CT scan patterns

Two investigators (a subspecialty thoracic radiologist and a respiratory physician) retrospectively reviewed the CT scans at five levels: (1) origin of great vessels; (2) carina; (3) pulmonary venous confluence; (4) between levels (3) and (5); and (5) 1 cm above the right hemi-diaphragm. An imaging example of a CT scans at five levels can be found in Supplementary Figure 1.

The investigators were blinded to outcomes. The CT assessment was consensus based.

Based on the study of Desai et al., the following features were quantified at each level: ground-glass opacification...
(GGO) proportion (GGO percentage of the total lung parenchyma), reticulation proportion (reticulation percentage of the total lung parenchyma), the overall extent of parenchymal lung disease (including GGO, reticulation and consolidation) and fibrosis coarseness score [7]. A reticular pattern was defined as interlobular septal thickening, intralobular interstitial thickening, wall cysts or honeycombing, peribronchovascular interstitial thickening and traction bronchiectasis/bronchiolectasis. The GGO pattern was defined as a hazy increase in opacity with preservation of bronchial and vascular markings. The coarseness score was determined as follows: (0) no fibrosis; (1) fine intralobular fibrosis; (2) microcystic reticular pattern comprising air spaces smaller than or equal to 4 mm in diameter; and (3) a macrocystic reticular pattern comprising air spaces larger than 4 mm in diameter. The overall coarseness score for each patient was calculated by summing the scores at five levels [7]. Imaging examples of the CT coarseness score can be found in Fig. 1.

Statistical analysis
The Mann–Whitney U-test and chi-squared test were used to compare patient characteristics and CT features between survivors and non-survivors. Analyses were carried out using SPSS for Mac. A p value of less than 0.05 was used as the cut-off for significance.

Results
Fifteen patients with ILD-associated ARF were admitted to the ICUs of the two university hospitals within the study period (shown in Table 1 and Supplementary Table 1). There were 5 patients (33%) with CTD-associated ILD, 7 (47%) with other ILD and 3 (20%) with vasculitis (shown in Table 2). Three patients (20%) had previously been diagnosed with ILD, while 12 (80%) were diagnosed with ILD upon admission. The median age was 56 years (IQR, 44–62), ten patients (67%) were male, and 8 (53%) were ever-smokers. The most frequent comorbidities reported in these patients were systemic autoimmune disease (53%), cardiovascular disease (27%), diabetes (20%) and hypertension (13%). Five out of 15 (33%) patients had a history of cancer (clinically undetectable and without active treatment during the study).

All patients had severe, steroid-refractory ARF requiring invasive mechanical ventilation and received cyclophosphamide in addition to standard care, including empirical antibiotic therapy or selective digestive decontamination (SDD) and (methyl)prednisolone (shown in Table 1). According to ILD guidelines 1000 mg methylprednisolone was given for 3 days [4]. To exclude respiratory infections (bacterial, fungal, viral), bronchoscopy with bronchoalveolar lavage (BAL) was performed in all patients prior to the administration of methylprednisolone and cyclophosphamide. The median time between the administration of methylprednisolone and cyclophosphamide was 7 days (IQR 3–10). Only two patients (13%) had positive BAL culture results before the initiation of cyclophosphamide therapy (shown in Table 1). Before cyclophosphamide therapy, the median number of leukocytes was $13.8 \times 10^9/L$ (IQR 10.1–20.5).

Four patients (27%) received 750 mg/m$^2$ cyclophosphamide; 8 patients (53%) received 600 mg/m$^2$; 2 patients (13%) received 500 mg/m$^2$ (dose adjustments because of impaired renal function); and 1 patient (7%) received a daily oral dose of 2 mg/kg. Leukopenia (defined as leukocytes $< 4 \times 10^9/L$) occurred in 2 patients after cyclophosphamide therapy and lasted for 5–9 days. Central line-associated bloodstream infection (n = 2; 13%) and ventilator-associated pneumonia (n = 2; 13%) were the
| Case | Sex (f/m) | Age (years) | Smoking (Y/N) | Comorbidity/ history | Diagnosis | CT findings | Pathology | BAL | Antibiotics | Therapy (cd) | In-hospital outcome, cause of death |
|------|-----------|-------------|---------------|----------------------|-----------|-------------|-----------|-----|-------------|-------------|-------------------------------|
| 1    | F         | 62          | Y             | Dermato-myositis     | Anti-MDA5 dermato-myositis | OP with architectural distortion | N/A       | ng  | Augmentin, ceftazidime | MPS 1 g CYC 600 mg/m² | Death, progressive respiratory failure |
| 2    | M         | 60          | N             | UCTD                 | UCTD-ILD | OP with architectural distortion | N/A       | ng  | SDD | MPS 3 g CYC 600 mg/m² | Survival |
| 3    | F         | 60          | N             | Medium-size-artery vasculitis | Diffuse GGO and consolidation | Vasculitis DAH | ng       | SDD | MPS 6 g CYC 750 mg/m² IVG | Survival |
| 4    | M         | 41          | N             | GPA                  | GPA       | Diffuse GGO | Eosinophilic necrotizing granulomatous inflammation | ng | SDD | MPS 3 g Continuous oral CYC 2 mg/kg Plasmapheresis | Survival |
| 5    | F         | 40          | N             | Neuro-fibromatosis type 1 RA | ANCA-negative small vessel vasculitis | Diffuse GGO | Vasculitis DAH | ng | SDD | MPS 12 g CYC 750 mg/m² IVG Plasmapheresis | Death MOF |
| 6    | M         | 61          | N             | None                 | Methotrexate-induced lung injury | Fibrotic NSIP | N/A       | SDD | moxifloxacin | MPS 3 g CYC 600 mg/m² | Survival |
| 7    | M         | 55          | Y             | Alcoholism, coronary heart disease | AIP | Diffuse GGO with architectural distortion | N/A       | ng  | Augmentin, Doxycycline | MPS 3 g CYC 500 mg/m² ECLA | Death Progressive respiratory failure |
| 8    | M         | 44          | Y             | SLE                  | SLE-related ILD | NSIP | N/A       | CMV | Ganciclovir | MPS 3 g CYC 600 mg/m² Plasmapheresis | Survival |
| 9    | M         | 72          | Y             | Poliomyelitis PMH: esophageal carcinoma | AIP | Diffuse GGO with architectural distortion | N/A       | ng  | Oseltamivir, Gatifloxacin, Erythromycin | MPS 3 g CYC 600 mg/m² | Survival |
| 10   | M         | 52          | N             | MCTD                 | MCTD-ILD | NSIP | NA        | Saureus | SDD | flucloxacillin | MPS 3 g CYC 500 mg/m² | Survival |
| 11   | F         | 38          | N             | SLE                  | SLE | Diffuse GGO | N/A       | ng  | Gatifloxacin, Azithromycin | MPS 3 g Plasmapheresis CYC 750 mg/m² | Survival |
| 12   | F         | 68          | Y             | PMH: breast cancer and esophageal carcinoma | Unclassified ILD with signs of fibrosis | Fibrosis with organization | ng | SDD | MPS 6 g CYC 600 mg/m² | Death Progressive respiratory failure |
| 13   | M         | 71          | Y             | AF, HPT, RA          | AIP | Diffuse GGO with architectural distortion | DAD       | ng  | Gatifloxacin | MPS 3 g CYC 600 mg/m² | Survival |
Table 1 (continued)

| Case | Sex (f/m) | Age (years) | Smoking (Y/N) | Comorbidity/history | Diagnosis | CT findings | Pathology | BAL | Antibiotics | Therapy (cd) | In-hospital outcome, cause of death |
|------|-----------|-------------|---------------|--------------------|-----------|-------------|-----------|-----|-------------|--------------|-------------------------------------|
| 14 M | 54        | Y           | DM, PMH: Hodgkin lymphoma | EAA | Diffuse GGO | N/A | ng | SDD | MPS 3 g CYC 600 mg/m² | Death Blocked tracheotomy Progressive respiratory failure |
| 15 M | 56        | Y           | DM, HPT, COPD | Unclassified ILD | Unclassified ILD with signs of fibrosis | DAD | ng | Augmentin Giprofloxacin³ | MPS 3 g CYC 600 mg/m² | Death |

AF, atrial fibrillation; AIP, acute interstitial pneumonia; ANCA, anti-neutrophil cytoplasmic antibody; AVNRT, atrioventricular nodal reentry tachycardia; COPD, chronic obstructive pulmonary disease; cd, cumulative dose; CT, computed tomography; CYC, cyclophosphamide; DAD, diffuse alveolar damage; DM, diabetes mellitus; EAA, extrinsic allergic alveolitis; ECLA, extra corporeal lung assist; GGO, ground glass opacity; GPA, granulomatosis with polyangiitis; HPT, hypertension; ICU, intensive care unit; ILD, interstitial lung disease; IVIG, intravenous immunoglobulin; LOS, length of stay; MCTD, mixed connective tissue disease; MOF, multiple organ failure; MPS, methylprednisolone; N/A, not applicable; ng, no growth; NHL, non-Hodgkin lymphoma; NSIP, non-specific interstitial pneumonia; OP, organizing pneumonia; OSAS, obstructive sleep apnoea syndrome; PMH, past medical history; RA, rheumatoid arthritis; SDD, selective digestive decontamination; SLE, systemic lupus erythematosus; UCTD-ILD, undifferentiated connective tissue disease associated interstitial lung disease

a Empirical antibiotic therapy
b MPS 1000 mg/day for 3 days

c Cyclophosphamide single dose
In this study, we report the in-hospital mortality, clinical response and radiologic characteristics of cyclophosphamide-treated mechanically ventilated patients with ILD-associated ARF. We found an overall in-hospital mortality rate of 40%. This is in line with the recent case series of Schulze et al. on 14 patients with ILD-associated ARF treated with cyclophosphamide. In this study, cyclophosphamide therapy was associated with a favourable outcome. However, only the minority of patients had non-vasculitis ILD [8]. Compared to previous reports on mixed ILD-associated ARF not treated with cyclophosphamide, we found lower mortality rates (40% vs 62–67%) [1–3]. A systematic review, including 50 studies on patients admitted to the intensive care unit (ICU) with ILD-associated ARF, showed overall in-hospital mortality rates in mechanically ventilated patients of 67% in mixed-ILD and 77% in IPF [9]. Consistent with previous studies, we found that CTD-associated ILD and vasculitis were associated with a lower risk of death than other ILDs (20% and 33% vs 57%) [1, 2, 5]. For life-threatening vasculitis, the following treatment strategies are well known and in accordance with current guidelines: glucocorticoids and either cyclophosphamide or rituximab [5]. Reported ICU survival rates amongst patients with vasculitis-associated ARF range from 25 to 50% [10]. For non-vasculitis, ILD data are scarce, and given the poor prognosis, add-on treatments are needed. Our findings might contribute to the awareness of cyclophosphamide as a treatment option for patients with ARF requiring ICU care, particularly in patients with vasculitis-associated ILD and MCTD-ILD.

Patients with IPF were not included in the study since in the participating hospitals, patients with IPF are rarely admitted to the ICU and generally treated with intravenous corticosteroids alone.

Radiologic evaluation through computed tomography (CT) is essential for the characterization and classification of ILD. In a retrospective analysis of 160 patients with ILD admitted to an ICU, analysis of the 76 with CT scans revealed a higher percent of fibrosing ILD among those who did not survive their ICU stay [11]. However, only 12 of the 160 patients were intubated. The CT scan analysis in our study might be used to predict the prognosis in ILD patients with more severe respiratory failure requiring invasive ventilation. Nevertheless, a larger confirmatory study is needed.

One of the most compelling observations of this study is the significantly higher ground-glass opacification (GGO) proportion in non-survivors than in survivors (71% vs 45%, respectively). The greater proportion of GGOs might be associated with more widespread...
impairment of alveolar and interstitial space and more prominent reduction of the surface for gas exchange. Therefore, the amount of GGO may be useful in predicting severe disease and the need for aggressive therapy. Furthermore, non-survivors had higher reticulation and fibrosis coarseness scores (26 vs 8; 7 vs 1,

| CT pattern                                      | Survivors (n = 9) | Non survivors (n = 6) | p value |
|------------------------------------------------|------------------|-----------------------|---------|
| Ground-glass opacification proportion (IQR)     | 45 (30–56)       | 71 (52–82)            | 0.034   |
| Reticulation proportion (IQR)                   | 8 (0–22)         | 26 (8–45)             | 0.150   |
| Overall extent of parenchymal lung disease (IQR)| 84 (63–92)       | 88 (75–91)            | 0.906   |
| Coarseness score, median (IQR)                  | 1 (0–5)          | 7 (4–10)              | 0.066   |

CT, computed tomograph; IQR, interquartile range
respectively). This might imply that a poor prognosis in ILD-associated ARF is associated with the initiation of the fibrotic process. The overall extent of disease may not be that significant, since it is partly determined by consolidation, which may be reversible.

The P/F ratio might be used to predict mortality in ARDS [12]. In our study, non-survivors have overall lower P/F ratio and Cdyn levels at baseline and 3 days after cyclophosphamide treatment. Given the small sample size, this difference did not reach statistical significance. There was a marked increase in the P/F ratio and Cdyn in survivors after 3 days of cyclophosphamide therapy. In non-survivors, the P/F ratio remained virtually unchanged, and Cdyn actually decreased (Table 3, Fig. 2). As such the P/F ratio and Cdyn could potentially be used to monitor the response to cyclophosphamide. Although P/F ratio and Cdyn seem to improve after methylprednisolone initially (Table 3), these patients were not able to wean from the ventilator or make further improvements after steroid therapy. Furthermore, the median time to respond to cyclophosphamide, defined as extubation or a successful weaning course, was 9 days. This may be useful for clinicians seeking to estimate time to treatment effect.

Table 4 Physiology and ventilator parameters in survivors and non-survivors

|                      | Survivors | Non-survivors | p value |
|----------------------|-----------|---------------|---------|
| SOFA                 |           |               |         |
| P/F ratio 1 day before MPS a (mmHg) | 156 (140–187) | 122 (83–153) | 0.119   |
| P/F ratio 3 days after MPS (mmHg) | 182 (156–221) | 113 (99–187) | 0.091   |
| P/F ratio 1 day before CYC (mmHg) | 129 (98–166) | 113 (80–131) | 0.214   |
| P/F ratio 3 days after CYC (mmHg) | 220 (159–270) | 114 (69–207) | 0.079   |
| Cdyn 1 day before MPS (mL/cmH2O) | 59 (34–87) | 20 (17–42) | 0.111   |
| Cdyn 3 days after MPS (mL/cmH2O) | 63 (51–91) | 27 (14–61) | 0.077   |
| Cdyn 1 day before CYC (mL/cmH2O) | 75 (41–126) | 27 (8–63) | 0.442   |
| Cdyn 3 days after CYC (mL/cmH2O) | 92 (52–151) | 20 (9–36) | 0.063   |

Values are expressed as median and interquartile range (IQR)

CYC, cyclophosphamide; Cdyn, dynamic compliance; MPS, methylprednisolone; P/F ratio, PaO2/FiO2-ratio; SOFA, Sequential Organ Failure Assessment;
a Methylprednisolone 1 g/day for 3 days

Fig. 3  P/F ratio and dynamic compliance before and after cyclophosphamide therapy. o survivors; x non-survivors. a Case 7 was not shown: ECMO, therefore no realistic P/F ratio. b Case 9 was not shown: patient was extubated after cyclophosphamide treatment; therefore, Cdyn after cyclophosphamide was not available. c dyn: dynamic compliance; CYC: cyclophosphamide; P/F ratio: PaO2/FiO2-ratio
Cyclophosphamide is a highly potent immunosuppressant that comes with potential toxicities, including haemorrhagic cystitis, bone marrow suppression, increased risk of opportunistic infections, and malignancies [13]. However, the level of toxicity is related to the cumulative dose. In this study, only one cycle of cyclophosphamide was given. No severe adverse events were observed. Given the poor prognosis of ILD-associated ARF, the adverse event profile of cyclophosphamide is considered acceptable [10].

There are a number of limitations to our study that should be considered when interpreting our findings. First, as our study did not include a control group of untreated patients. Therefore, we cannot determine the impact of cyclophosphamide treatment on mortality in ILD-associated ARF. However, in our study the mortality of patients with ILD related ARF treated with cyclophosphamide was lower than the mortality in historical reports in patients not treated with cyclophosphamide. Second, the small size of our series limits the reliability of the results. Unfortunately, the low prevalence of ILD-associated ARF limits patient studies and data collection. Future studies in larger populations, each including a control group, are needed to confirm our findings.

Conclusion
In this retrospective study, we found a mortality rate of 40% in patients treated with cyclophosphamide for ILD-associated ARF. Connective tissue disease-associated ILD and vasculitis ILD were associated with a lower risk of death than other ILDs when treated with cyclophosphamide. Furthermore, between survivors and non-survivors, we found that the GGO proportion was significantly higher in non-survivors. The P/F ratio and Cdyn in survivors increased after 3 days of cyclophosphamide treatment.

Abbreviations
AIP: Acute interstitial pneumonia; BAL: Bronchoalveolar lavage; ARF: Acute respiratory failure; BTS: British Thoracic Society; Cdyn: Dynamic compliance; CT: Computed tomography; CTD: Connective tissue disease; EAA: Extrinsic allergic alveolitis; ECLA: Extracorporeal lung assist; GGO: Ground-glass opacification; ICU: Intensive care unit; ILD: Interstitial lung disease; IMV: Invasive mechanical ventilation; IPF: Idiopathic pulmonary fibrosis; LOS: Length of stay; P/F ratio: PaO2/FiO2 ratio; SDD: Selective digestive decontamination; SOFA: Sequential Organ Failure Assessment Score.

Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1186/s12890-021-01615-2.

Additional file 1. Supplementary Table 1: Physiological parameters and ventilator settings. *prone ventilation; **extracorporeal lung assist.

Authors’ contributions
JPG, EJN, REJ and APV wrote the manuscript and contributed the case data. JPG and IAB reviewed the CT scans. LMAH and PIB made substantial contributions to the design conception and have drafted the work and substantively revised it. All authors read and approved the final manuscript.

Availability of data and materials
The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

Declarations
Ethics approval and consent to participate
The Medical Ethics Review Board of the two participating university hospitals, The Academic Medical Center and the VU University Medical Center, waived the need for ethics approval and the need to obtain consent for the data collection, analysis and publication of the retrospectively obtained and anonymized data for this non-interventional study.

Consent for publication
All surviving patients provided written informed consent to the study. Written consent for publication was obtained from the next of kin of the deceased patients.

Competing interests
The authors declare that they have no competing interests.

Author details
1 Department of Intensive Care Medicine, Amsterdam University Medical Center, Location AMC, University of Amsterdam, Amsterdam, The Netherlands. 2 Department of Radiology, Amsterdam University Medical Center, Location AMC, University of Amsterdam, Amsterdam, The Netherlands. 3 Department of Respiratory Medicine, Amsterdam University Medical Center, Location VUMC, Vrije Universiteit, Amsterdam, The Netherlands. 4 Department of Intensive Care Medicine, Amsterdam University Medical Center, Location AMC, University of Amsterdam, Amsterdam, The Netherlands. 5 Department of Respiratory Medicine, Amsterdam University Medical Center, Location AMC, University of Amsterdam, Amsterdam, The Netherlands. 6 Department of Pulmonary Diseases, University Medical Center Groningen (UMCG), Hanzeplein 1, HP BB72, 9700 RB Groningen, The Netherlands.

Received: 19 February 2021 Accepted: 21 July 2021
Published online: 28 July 2021

References
1. Gannon WD, Lederer DJ, Biscotti M, et al. Outcomes and mortality prediction model of critically ill adults with acute respiratory failure and interstitial lung disease. Chest. 2018;153(6):1387–95.
2. Lee J, Yim JJ, Yang SC, et al. Outcome of patients with connective tissue disease requiring intensive care for respiratory failure. Rheumatol Int. 2012;32(11):3533–8.
3. Vial-Dupuy A, Sanchez O, Dousset B, et al. Outcome of patients with interstitial lung disease admitted to the intensive care unit. Sarcoïdosis Vasc Diffuse Lung Dis. 2013;30(2):134–42.
4. Wells AU, Hirani N, on behalf of the British Thoracic Society Interstitial Lung Disease Guideline Group, a subgroup of the British Thoracic Society Standards of Care Committee, in collaboration with the Thoracic Society Standards of Care Committee. BTS Standards of Care Committee. In: BTS Standards of Care Committee. BTS Standards of Care Committee. Diffuse Interstitial Lung Disease. 22th ed. London: British Thoracic Society; 2010. 135–40.
of Australia and New Zealand and the Irish Thoracic Society. Interstitial lung disease guideline: the British Thoracic Society in collaboration with the Thoracic Society of Australia and New Zealand and the Irish Thoracic Society. Thorax. 2008;63:v1–58.

5. Yates M, Watts RA, Bajema IM, et al. EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis. Ann Rheum Dis. 2016;75:1583–94.

6. American Thoracic Society, European Respiratory Society. American Thoracic Society/European Respiratory Society international multidisciplinary consensus classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med. 2002;165:277–304.

7. Desai SR, Veeraraghavan S, Hansell DM, et al. CT features of lung disease in patients with systemic sclerosis: comparison with idiopathic pulmonary fibrosis and nonspecific interstitial pneumonia. Radiology. 2004;232(2):560–7.

8. Schulze AB, Evers G, Kummel A, et al. Cyclophosphamide pulse therapy as treatment for severe interstitial lung diseases. Sarcoidosis Vasc Diffuse Lung Dis. 2019;36(2):157–66.

9. Huapaya JA, Wilfong EM, Harden CT, et al. Risk factors for mortality and mortality rates in interstitial lung disease patients in the intensive care unit. Eur Respir Rev. 2018;27:180061.

10. Semple D, Keogh J, Fomi L, et al. Clinical review: vasculitis on the intensive care unit—part 2: treatment and prognosis. Crit Care. 2005;9(2):193–7.

11. Shi S, Xiao Y, Qiu X, et al. Prognostic effects of clinical and CT imaging features on critically ill patients with interstitial lung disease hospitalized in respiratory intensive care unit. Sci Rep. 2019;9(1):17190.

12. Villar J, Ambros A, Solar JA, et al. PaO2/FIO2, and Plateau Pressure Score: a proposal for a Simple Outcome Score in patients with the acute respiratory distress syndrome. Study Crit Care Med. 2016;44(7):1361–9.

13. Barnes H, Holland AE, Westall GP. Cyclophosphamide for connective tissue disease-associated interstitial lung disease. Cochrane Database Syst Rev. 2018;1(1):CD010.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.